1. Home
  2. PIPR vs ERAS Comparison

PIPR vs ERAS Comparison

Compare PIPR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Piper Sandler Companies

PIPR

Piper Sandler Companies

N/A

Current Price

$60.99

Market Cap

5.5B

Sector

Finance

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$13.98

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PIPR
ERAS
Founded
1895
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.3B
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
PIPR
ERAS
Price
$60.99
$13.98
Analyst Decision
Buy
Buy
Analyst Count
5
10
Target Price
★ $74.75
$25.10
AVG Volume (30 Days)
671.9K
★ 5.1M
Earning Date
10-30-2026
11-12-2026
Dividend Yield
★ 1.27%
N/A
EPS Growth
N/A
★ 36.23
EPS
★ 2.65
N/A
Revenue
★ $1,904,217,000.00
N/A
Revenue This Year
$4.26
N/A
Revenue Next Year
$12.20
N/A
P/E Ratio
$23.68
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.35
$2.81
52 Week High
$309.45
$24.28

Technical Indicators

Market Signals
Indicator
PIPR
ERAS
Relative Strength Index (RSI) 35.47 44.12
Support Level N/A $13.18
Resistance Level $78.49 $15.71
Average True Range (ATR) 2.17 1.31
MACD -0.45 -0.12
Stochastic Oscillator 0.28 19.91

Price Performance

Historical Comparison
PIPR
ERAS

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: